See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, often used as a last-resort treatment for severe bacterial infections that are resistant to other antibiotics [1]. Several factors make tigecycline a preferred choice in certain situations:

1. Broad-spectrum activity: Tigecycline is effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria, making it a versatile antibiotic option [1][2].

2. Activity against drug-resistant bacteria: Tigecycline has been shown to be effective against many drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) [1][2].

3. Minimal cross-resistance: Due to its unique mechanism of action, tigecycline has minimal cross-resistance with other antibiotics, making it a valuable option when other antibiotics have failed [1][2].

4. Once-daily dosing: Tigecycline is administered as a once-daily intravenous infusion, which can improve patient compliance and convenience [1].

5. Safety profile: Tigecycline has a favorable safety profile, with nausea and vomiting being the most commonly reported adverse effects [1].

However, it is important to note that tigecycline has a higher mortality rate compared to other antibiotics in the treatment of certain infections, such as complicated skin and soft tissue infections and complicated intra-abdominal infections [1][2]. Therefore, the use of tigecycline should be carefully considered and balanced against the potential risks and benefits in each individual case.

Sources:
[1] FDA. (2017). Tygacil (tigecycline) prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021837s021s022s023s024lbl.pdf>
[2] DrugPatentWatch. (2021). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>